Want to see NEPH full AI Analyst Report?
NEPH Stock Chart & Stats
$5.01
<$0.01(0.48%)
At close: 4:00 PM EST
$5.01
<$0.01(0.48%)
Day’s Range― - ―
52-Week Range$2.66 - $6.42
Previous Close$1.57
Volume70.00
Average Volume (3M)75.62K
Market Cap
$39.63M
Enterprise Value$29.70
Total Cash (Recent Filing)$4.02M
Total Debt (Recent Filing)$968.00K
Price to Earnings (P/E)51.6
Beta-0.44
Next Earnings
Nov 05, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding10,856,546
10 Day Avg. Volume107,933
30 Day Avg. Volume75,620
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)5.08
Price to Sales (P/S)2.76
P/FCF Ratio31.48
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$6.00Price Target Upside19.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.04
Revenue Forecast (FY)$20.92M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables (razor-and-blades)Nephros’s business model generates recurring revenue from replacement filter cartridges and consumables after initial installations. This installed-base driven “razor-and-blades” dynamic creates predictable reorder streams, supports lifetime customer value, and reduces reliance on one‑time sales.
Conservative Balance Sheet And LiquidityLow leverage and a strengthened equity base provide financial flexibility to fund installations, R&D and market expansion without heavy interest burden. Debt-free positioning and ~ $4M cash (reported) reduce refinancing risk and help absorb temporary cash flow volatility.
Strong Programmatic Growth And Expanding FootprintConsistent programmatic installations and 23% recurring growth indicate successful adoption of service and replacement programs. A growing installed base (1,676 sites) and efforts to expand into broader commercial end markets increase addressable market and long‑term recurring revenue potential.
Bears Say
Negative Operating And Free Cash Flow (TTM)A TTM swing to negative operating and free cash flow threatens sustainability of growth investments and recurring operations. Even with prior positive cash generations, ongoing cash burn raises funding and working capital risks, pressuring liquidity if not reversed within months.
Gross Margin And Profit CompressionAn 8-point gross margin decline reflects structural cost pressures (tariffs, currency, mix) that materially reduce earnings power. If sustained, lower gross margins will compress operating leverage, reduce free cash generation and limit capital available for expansion and R&D.
Shift Into Lower-margin Commercial Markets And Pricing PressurePursuing larger addressable markets via lower‑margin commercial segments dilutes unit economics and invites competitive pricing. Over time this can reduce blended margins and necessitate greater investment in education, partnerships and service to retain customers and preserve recurring revenue.
NEPH FAQ
What was Nephros Inc’s price range in the past 12 months?
Nephros Inc lowest stock price was $2.66 and its highest was $6.42 in the past 12 months.
What is Nephros Inc’s market cap?
Nephros Inc’s market cap is $39.63M.
When is Nephros Inc’s upcoming earnings report date?
Nephros Inc’s upcoming earnings report date is Nov 05, 2026 which is in 103 days.
How were Nephros Inc’s earnings last quarter?
Nephros Inc released its earnings results on Jul 22, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of $0.003 by $0.007.
Is Nephros Inc overvalued?
According to Wall Street analysts Nephros Inc’s price is currently Undervalued.
Does Nephros Inc pay dividends?
Nephros Inc does not currently pay dividends.
What is Nephros Inc’s EPS estimate?
Nephros Inc’s EPS estimate is 0.02.
How many shares outstanding does Nephros Inc have?
Nephros Inc has 10,856,546 shares outstanding.
What happened to Nephros Inc’s price movement after its last earnings report?
Nephros Inc reported an EPS of $0.01 in its last earnings report, beating expectations of $0.003. Following the earnings report the stock price went up 1.671%.
Which hedge fund is a major shareholder of Nephros Inc?
Currently, no hedge funds are holding shares in NEPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nephros Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (19.76% Upside)
$6.00 (19.76% Upside)
Hedge Fund Trend
Decreased
By 11.5K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
226.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.12%
Trailing 12-Months
Company Description
Nephros Inc
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.
NEPH Stock 12 Month Forecast
Average Price Target
$6.00
▲(19.76% Upside)
Technical Analysis
Ownership Overview
4.81% Insiders
2.38% Mutual Funds
0.55% Other Institutional Investors
90.19% Public Companies and
Individual Investors









